Archer Aviation ( (ACHR) ) has fallen by -8.28%. Read on to learn why.
Claim 30% Off TipRanks
Trade ACHR with leverageArcher Aviation shares fell 8.28% over the past week as fresh short-seller pressure and renewed scrutiny of its electric air taxi program overshadowed otherwise supportive ownership and compensation news. The stock slid after Culper Research publicly reiterated its short position, accusing the pre-revenue eVTOL developer of misleading investors, halting flight testing for several months, lacking an airworthiness certificate for a key test aircraft, and still not finalizing the design of its Midnight model. These claims have stoked concerns about certification timelines, execution risk, and potential disclosure issues, weighing on sentiment despite the company’s earlier reports of test milestones and aircraft under assembly.
At the same time, Archer Aviation disclosed new Form 4 filings showing stock-based compensation awards to four senior executives, including its legal, finance, tech and administration chiefs. These restricted stock units, granted at no cost and vesting gradually from March 2026, are designed to retain key leaders and align them with long-term shareholder value, rather than signal insider buying or near-term performance. For investors, the grants highlight how Archer is using equity rather than cash to keep its leadership team in place as it navigates an intensive development and certification phase.
Balancing the negative headlines, institutional ownership and analyst views remain relatively constructive. A recent Schedule 13G showed State Street holding about 5% of Archer Aviation in a passive, index-driven position, signalling the stock’s growing inclusion in mainstream portfolios rather than an activist bet. Street analysts maintain a Moderate Buy rating with price targets implying significant upside from current levels, but the week’s 8.28% decline underscores that near-term trading will likely remain volatile and highly sensitive to any new information on flight testing, regulatory progress and the credibility of short-seller allegations.